Phenome-Wide Association Study of Rheumatoid Arthritis Subgroups Identifies Association Between Seronegative Disease and Fibromyalgia

Arthritis and Rheumatology

Volumn 69, Issue 2, 2017, Pages 291-300

  Doss, Jayanth ^a   Mo, Huan ^b   Carroll, Robert J ^c   Crofford, Leslie J ^c   Denny, Joshua C ^c  

^a DUKE UNIVERSITY   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; ALGORITHM; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTRONIC HEALTH RECORD; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FIBROMYALGIA; FOLLOW UP; GENOME-WIDE ASSOCIATION STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYALGIA; MYOSITIS; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SERODIAGNOSIS; SEROTYPE; BLOOD; COMPLICATION; GENETIC ASSOCIATION STUDY; GENETICS; MIDDLE AGED; SEROLOGY;

ARTHRITIS, RHEUMATOID; FEMALE; FIBROMYALGIA; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; SEROLOGIC TESTS;

EID: 85010908256     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39851     Document Type: Article

References (47)

1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
2. BRASS: Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study web site. URL: http://www.brassstudy.org/brass-information/overview/.
3. Maehlen MT, Olsen IC, Andreassen BK, Viken MK, Jiang X, Alfredsson L, et al. Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis. Ann Rheum Dis 2015;74:762–8.
4. Greiner A, Plischke H, Kellner H, Gruber R. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 2005;1050:295–303.
5. Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005;32:231–8.
6. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406–15.
7. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published errata appear in N Engl J Med 2001;344:76, 240]. N Engl J Med 2000;343:1586–93.
8. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400–11.
9. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377–86.
10. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625–39.
11. Alarcón GS, Koopman WJ, Acton RT, Barger BO. Seronegative rheumatoid arthritis: a distinct immunogenetic disease? Arthritis Rheum 1982;25:502–7.
12. Mongan ES, Cass RM, Jacox RF, Vaughan JH. A study of the relation of seronegative and seropositive rheumatoid arthritis to each other and to necrotizing vasculitis. Am J Med 1969;47:23–35.
13. Burns TM, Calin A. The hand radiograph as a diagnostic discriminant between seropositive and seronegative “rheumatoid arthritis”: a controlled study. Ann Rheum Dis 1983;42:605–12.
14. Aubart F, Crestani B, Nicaise-Roland P, Tubach F, Bollet C, Dawidowicz K, et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 2011;38:979–82.
15. Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson W, Symmons D, et al. Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008;58:359–69.
16. Gonzalez A, Icen M, Kremers HM, Crowson CS, Davis JM, Therneau TM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 2008;35:1009–14.
17. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007;46:342–9.
18. Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212–7.
19. Kurreeman F, Liao K, Chibnik L, Hickey B, Stahl E, Gainer V, et al. Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. Am J Hum Genet 2011;88:57–69.
20. Liao KP, Cai T, Gainer V, Goryachev S, Zeng-Treitler Q, Raychaudhuri S, et al. Electronic medical records for discovery research in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:1120–7.
21. Carroll RJ, Thompson WK, Eyler AE, Mandelin AM, Cai T, Zink RM, et al. Portability of an algorithm to identify rheumatoid arthritis in electronic health records. J Am Med Inform Assoc 2012;19:e162–9.
22. Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics 2010;26:1205–10.
23. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol 2013;31:1102–11.
24. Neuraz A, Chouchana L, Malamut G, le Beller C, Roche D, Beaune P, et al. Phenome-wide association studies on a quantitative trait: application to TPMT enzyme activity and thiopurine therapy in pharmacogenomics. PLoS Comput Biol 2013;9:e1003405.
25. Liao KP, Kurreeman F, Li G, Duclos G, Murphy S, Guzman R, et al. Associations of autoantibodies, autoimmune risk alleles, and clinical diagnoses from the electronic medical records in rheumatoid arthritis cases and non–rheumatoid arthritis controls. Arthritis Rheum 2013;65:571–81.
26. Roden D, Pulley J, Basford M, Bernard G, Clayton E, Balser J, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 2008;84:362–9.
27. Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics 2014;30:2375–6.
28. Center for Precision Medicine. PheWAS R Package page. URL: http://knowledgemap.mc.vanderbilt.edu/research/content/phewas-r-package.
29. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia. J Rheumatol 2004;31:695–700.
30. Pollard LC, Kingsley GH, Choy EH, Scott DL. Fibromyalgic rheumatoid arthritis and disease assessment. Rheumatology (Oxford) 2010;49:924–8.
31. Lee YC, Lu B, Boire G, Haraoui B, Hitchon CA, Pope JE, et al. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Ann Rheum Dis 2013;72:949–54.
32. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600–10.
33. Ge HY, Wang Y, Fernández-de-las-Peñas C, Graven-Nielsen T, Danneskiold-Samsøe B, Arendt-Nielsen L. Reproduction of overall spontaneous pain pattern by manual stimulation of active myofascial trigger points in fibromyalgia patients. Arthritis Res Ther 2011;13:R48.
34. Lapossy E, Maleitzke R, Hrycaj P, Mennet W, Müller W. The frequency of transition of chronic low back pain to fibromyalgia. Scand J Rheumatol 1995;24:29–33.
35. Catrina AI, Ytterberg AJ, Reynisdottir G, Malmström V, Klareskog L. Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis. Nat Rev Rheumatol 2014;10:645–53.
36. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L, for the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A gene–environment interaction between smoking and shared epitope genes in HLA–DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004;50:3085–92.
37. Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997;56:463–9.
38. De Rooy DP, van Nies JA, Kapetanovic MC, Kristjansdottir H, Andersson ML, Forslind K, et al. Smoking as a risk factor for the radiological severity of rheumatoid arthritis: a study on six cohorts. Ann Rheum Dis 2014;73:1384–7.
39. Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, et al. Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 2013;65:1243–50.
40. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010;62:1583–91.
41. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics: a large multicentre UK study. Rheumatology (Oxford) 2014;53:1676–82.
42. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294–300.
43. Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:990–7.
44. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
45. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
46. PCORI: Patient-Centered Outcomes Research Institute web site. URL: http://www.pcori.org/.
47. Gottesman O, Kuivaniemi H, Tromp G, Faucett WA, Li R, Manolio TA, et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med 2013;15:761–71.